16.95
+6.94%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Perrigo Company
From its filings with the US Securities and Exchange Commission
Perrigo Company is based in Dublin 2, Ireland and is incorporated in Ireland. Its shares trade on NYSE under the ticker PRGO. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $4.25bn and a net loss of $1.43bn. At that date it held total assets of $8.54bn and shareholders' equity of $2.94bn. By region, United States accounted for 59.7%, followed by Europe at 38.0% and All Other Countries at 2.3%.
Perrigo is a leading pure-play self-care company with more than a century of providing high-quality health and wellness solutions to meet the evolving needs of consumers. As one of the originators of the over-the-counter ("OTC") self-care market, Perrigo is led by its vision "To Provide The Best Self-Care For Everyone" and its purpose to "Make Lives Better Through Trusted Health and Wellness Solutions, Accessible To All".
Perrigo provides access to trusted self-care solutions that can be used without the need to visit a health practitioner for a prescription. Guided by our vision and purpose, our strategic goal is to create sustainable and value accretive growth by 1) delivering consumer preferred brands and innovation, 2) driving category growth with our customers, 3) powering our business with our world-class, quality assured supply chain, including a focus on sustainability with meaningful goals to reduce greenhouse gas emissions, water, and waste, in addition to increasing the recyclability of our packaging, and 4) evolving our global organization to one cohesive operating model. Our unique competency is to deliver health and wellness solutions across multiple price and value tiers that improve access and choice for consumers.
Quoted from its 10-K, filed 26 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 17 Dec 1991
- Employees
- 8,100
- Website
- perrigo.com ↗
- Head office
- THE SHARP BUILDING, DUBLIN 2, L2, D02 TY74
- Incorporated in
- L2
- Classification
- Pharmaceutical Preparations
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Mr. Orlando AshfordIndependent Chairman of the Board$532,990
- Mr. Patrick Lockwood-TaylorPresident, Chief Executive Officer, Director, since 2023$7.8m
- Mr. Eduardo BezerraChief Financial Officer, Executive Vice President$3.2m
- Mr. Robert WillisChief Human Resources Officer, Executive Vice President
- Ms. Abigail LennoxExecutive Vice President, Chief Scientific Officer
- Mr. Charles AtkinsonExecutive Vice President, General Counsel, Company Secretary
- Dr. David BallExecutive Vice President, Chief Brand and Digital Officer
- Mr. Roberto KhouryExecutive Vice President, Chief Commercial Officer$1.9m
- Mr. Matt WintermanExecutive Vice President - Product Supply, Operations Strategy and Transformation Officer
- Mr. Bradley AlfordIndependent Director$387,492
- Ms. Julia BrownIndependent Director$239,797
- Mr. Kevin EganIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 64
- Environment
- 73
- Social
- 79
- Governance
- 40
- Direct emissions (scope 1)
- 68,712 t
- Energy emissions (scope 2)
- 80,712 t
- Value chain emissions (scope 3)
- 614,443 t
- Women in the workforce
- 48%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Established Presence: Perrigo Company PLC has a strong and established presence in the pharmaceutical and consumer healthcare markets.
- Diverse Product Portfolio: The company offers a wide range of generic drugs, over-the-counter medicines, and healthcare products, providing a stable revenue stream.
- Global Reach: Perrigo operates in multiple countries, allowing it to tap into various markets and reach a large customer base.
Weaknesses
- Regulatory Challenges: As a pharmaceutical company, Perrigo faces strict regulations and compliance requirements, which can increase costs and create barriers to market entry.
- Dependence on Key Retailers: The company relies heavily on a few key retailers for its product distribution, making it vulnerable to any changes in these partnerships.
Opportunities
- Growing Generics Market: The increasing demand for affordable healthcare products presents an opportunity for Perrigo to expand its generic drug business.
- Expansion into Emerging Markets: Perrigo can explore untapped markets in developing countries where access to affordable healthcare is a pressing need.
- Innovation and New Product Development: Investing in research and development can lead to the creation of innovative products, providing a competitive edge.
Threats
- Intense Competition: The pharmaceutical and consumer healthcare industries are highly competitive, with numerous players vying for market share.
- Patent Expirations: The expiration of patents on certain drugs can lead to increased competition from generic manufacturers, impacting Perrigo's sales and profitability.
- Economic Factors: Changes in economic conditions, such as recessions or currency fluctuations, can affect consumer spending on healthcare products.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.